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The ligand-receptor interactions based on silicon technology 
ABSTRACT 
Characterization of the extraordinary complexity 
of ligand-receptor interactions, represent one of 
the prominent goals in today biological research. 
To approach this theme, we explored the use of 
porous silicon (pSi) technology for the 
construction of a biotechnological device, in 
which the ligand-receptor interactions are 
revealed by means of laser optical measurements. 
Here we report the settling of chemical procedures 
for the functionalization of the silicon wafers and 
for the subsequent anchoring of biological 
molecules such as a purified murine monoclonal 
antibody (UN1 mAb), an antibody anti-P8 protein 
of M13 phage and an antibody anti-A20 murine 
lymphoma cell line. The optical analysis of the 
interaction on the biochips between the bound 
biomolecules and their corresponding ligands 
indicated that the pSi is suitable for this 
application. 
KEYWORDS: silicon biochip, chemical 
functionalization, fluorescence labelling, M13 
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ABBREVIATIONS 
APTES, Aminopropyltriethoxysilane; a.u., 
absorbance units; cSI, crystal silicon; FITC, 
fluorescein isothiocyanate; FT-IR, Fourier 
transformed infrared spectroscopy; GA, 
glutaraldheyde; HEPES, 4-(2-hydroxyethyl)-1-
piperazineethanesulfonic acid; mAb, monoclonal 
antibody; ON, overnight; OSA, optical spectra 
analysis; PA, protein A; PBS, phosphate buffer 
saline; pSI, Porous silicon; RT, room temperature; 
SIO, silicon oxide 
 
INTRODUCTION 
The extraordinary complexity of ligand-receptor 
interaction limits our knowledge of the molecular 
mechanisms of tumorigenesis and is a major 
obstacle in developing cancer-specific therapeutic 
agents. Pioneer large-scale analysis of protein 
complexes has revealed that a given protein can 
physically associate to tens (>200) of different 
proteins [1]. In the case of eukaryotic cells, 
20,000 proteins or more may establish an 
extraordinary large number of functional 
interactions with cell receptors, making unrealistic 
a systematic approach where each ligand-receptor 
interaction is studied as a single network. To 
overcome these hurdles, we dedicated to a 
comprehensive analysis of ligand-receptor 
interactions in mammalian cells [2, 3], developing 
a novel biochip based on the chemical and optical 
properties of porous silicon [4]. In this device, the 
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Figure 1A shows the corresponding schematic 
chemical reaction occurring in the first two 
steps. 
In the third step, the chip was treated at RT 
for 30 minutes with a solution of 2.5% 
Glutaraldehyde (GA) in 20 mM HEPES, pH 7.4. 
The chemical bond APTES-GA was then 
stabilized by incubating the supports at RT for 
2 hours in 50 mM NaCNBH3 in 10 mM NaOH 
(Figure 1B). The bifunctional GA linked to the 
surface was then available for the subsequent 
linkage of PA. 2 mg/ml of commercial 
recombinant PA from Staphylococcus aurens in 
0.1 M sodium carbonate, pH 9 were incubated 
overnight (ON) at 4°C with the functionalized 
wafers [8]. After extensive washes of the biochips 
surface with water, specific antibody was bound 
to the PA ON at 4°C at a concentration of 
2 mg/ml in 1x PBS (Figure 1C). 
 
Interaction between a monoclonal antibody 
and its ligand peptide 
The progressive functionalization steps of the 
porous silicon biochip were analyzed by 
ellipsometry, optical measurements and FT-IR 
spectroscopy (not shown). As reported in Table 1, 
each chemical treatment induced the formation of 
 
 
 
 
ligand-receptor interaction is transduced, at 
high levels of specificity and sensitivity, in an 
optical signal generated by change of pSI 
refractive index [5-7]. The strategy includes the 
chemical functionalization of the silicon surface 
by using bifunctional linker molecules; the 
anchoring to the functionalized surface of specific 
antibodies; the biochip activity assay by 
evaluating its ability to reveal the corresponding 
antibody-ligand interaction. 
Silicon wafer chemical functionalization 
The binding of an antibody to the biochip was 
achieved through the specific molecular 
interaction between the antibody and protein A 
(PA). We adopted the following procedure in 
order to bind protein A to the wafer. pSI or crystal 
silicon (cSI) surface was functionalized by a first 
step oxidation process, performed at 900°C for 
15 minutes, that produced a layer of about 80 nm 
of silicon oxide (SIO). In the second step, the 
oxidized wafer was treated at room temperature 
(RT) for 30 minutes with a water solution 
containing 5% of APTES (aminopropyl- 
triethoxysilane) in 50% methanol, followed by 
several washes in 50% methanol and drying under 
a stream of nitrogen. The wafer was then heated 
on a heating plate at 100°C for 10 minutes. 
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Figure 1. Reaction scheme of the porous silicon chemical functionalization process.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Molecular interactions on silicon biochips 
  
 
 
 
 
 
 
 
 
 
a chemical layer with a total increase of the 
surface thickness of about 85 nm. 
The fabrication process of the biochip was 
also monitored by fluorescence intensity 
measurements starting from PA treatment step 
using a fluorescence macroscope (Z16 APO) 
equipped with a high precision 100 W Hg lamp. 
Leica QWIN V3 software allowed image 
computation. Each reaction step was carried out 
using fluorescent biomolecules labelled with 
fluorescein or rhodamine (fluorescein green, 
FITC, λext, 492 nm, λem, 520 nm; rhodamine 
red, λext, 570 nm, λem, 590 nm), thus allowing 
determining their chemical anchoring to the 
biochip surface. The antibody used was UN1, a 
murine monoclonal antibody (UN1 mAb) 
previously selected for the specific reactivity with 
human thymocytes as compared to peripheral 
blood cells [9, 10]. The antigen recognized by 
UN1 mAb is a 100-120 kDa transmembrane 
glycoprotein showing biochemical features of cell 
membrane-associated mucin-like glycoproteins, a 
class of macromolecules that are involved 
in cell-to-cell interactions and cancer progression 
[11, 12]. UN1 mAb interacts at high 
affinity with a specific 23mer peptide, G23 
(SFAATPHTCKLLDECVPLWPAEG), with a 
kd = 0.155 ± 0.003 µM. To determine the 
optimum concentration of UN1 mAb binding to 
the biochip, an antibody titration uptake was 
performed. As reported in Figure 2, the uptake of 
UN1 mAb on the biochip, evaluated by OSA 
(Figure 2A) and fluorescence measurements  
(Figure 2B), increased at increasing concentration 
of antibody and reached a plateau at a 
concentration of about 1.0 mg/ml corresponding 
to 6.8 µM. In addition, reported in Figure 2C, 
the amount of fluorescence intensity of 
labeled G23 bound to the biochip increased
 
 
Table 1. Thickness of the biochip chemical 
layer after functionalization steps. 
Layer Thickness (nm) 
IgG 6.18 
PA 0.48 
GA 2.31 
APTES 2.95 
SIO 74.91 
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Figure 2. Titration of the binding of UN1 mAb to the 
PA-functionalized biochip. A) Average difference 
of the refractive index (Uλ) of pSI at increasing 
concentration of UN1 mAb. B) Fluorescence intensity 
of the biochip at increasing concentration of UN1 mAb, 
(Q) no-wash, (O) wash, (V) dialysis. C) Fluorescence 
intensity of the biochip at increasing concentration of 
labelled G23. 150-200 µg of antibody (or peptide) in 
0.1 M NaHCO3 were mixed with 5-10 µl of rhodamine 
(0.5-1 µg in 20 µl DMSO) in a final volume of 100 µl 
and incubated for 1 hour at RT. The labelled molecule 
was then purified by Sephadex G50 gel filtration 
(0.5 x 5.0 cm spin-down column at 3000 rpm for 
30 seconds). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
proportionally to the increase of the peptide 
concentration up to about 400 µM. 
The UN1 mAb concentration determined for the 
saturation of biochip was then used to test the 
ability of the biochip to bind its ligand peptide, 
G23. In Figure 3 are reported the fluorescence 
images of the biochips during its fabrication 
and monitored by using for each step the 
corresponding labelled biomolecules (Figure 3A-
3C). The fluorescence intensity observed appeared 
to decrease with the progression of the biochip 
construction steps. This behaviour was probably 
due to a concomitant reduction of the binding 
efficiency of the biochip in terms of yield. 
Nevertheless, the results obtained strongly 
indicated that the biochip is able to reveal the 
specific interaction antibody-ligand (UN1 mAb-G23). 
 
Interaction between antibody anti-P8 M13 
protein and M13 phage on silicon wafer 
The strategy is directed toward the fabrication of a 
new system-array for the screening of random 
peptide libraries (RPL) displayed on phages 
to identify novel peptide ligands of highly 
polymorphic (>10E11) receptor such as B cell 
(BCR) and T cell receptor (TCR) complexes of 
B and T cells, respectively. To fulfill this task, we 
started to build a system able to detect the 
molecular interaction between the antibody 
anti-P8 M13 phage protein and the M13 phage. 
Having settled the condition to construct a 
PA-based pSI-biochip, we applied this fabrication 
procedure to crystalline silicon. Therefore, the 
antibody anti-M13 phage was bound to 
PA-functionalized cSI biochips at a concentration 
6.8 µM, ON at 4°C. In order to eliminate 
nonspecific binding of the phage to the silicon 
support, before the incubation with the phage
 
 
solution, the biochips were passivated by 
incubation with a solution of 5% nonfat dried 
milk in 1x PBS at RT for 1 hour. As negative 
control, we used UN1 mAb that does not bind to 
the M13 phage. As reported in Figure 4, the 
M13 phage, labelled with FITC, did bind to the 
biochip containing the anti-P8 phage antibody 
(AbAnti-P8) whereas it did not bind to the 
biochip containing UN1 mAb and to the non-
functionalized biochip treated with anti-P8 phage 
antibody. Evaluation of fluorescence intensity (a.u.) 
at macroscope showed a high value only in the 
case of biochip A (chip A, after washes: 32.81, 
after dialysis: 23.53; chip B, after washes: 25.85, 
after dialysis: 3.0; chip C, after washes: 15.6, after 
dialysis: 3.0). Also the ellipsometric analysis of 
the samples reported in Table 2 indicated a higher 
increase of the biochip thickness only in the case 
of wafer A thus indicating the effective anchoring 
of the M13 phage to the biochip throughout its 
interaction with antibody anti-P8. 
 
Immobilization on the silicon wafer of a 
murine lymphoma cells 
We next explored the application of the 
functionalized biochip for its capability to bind a 
cell line. As model, it was chosen a murine 
lymphoma cell line (A20) expressing high levels 
of membrane IgG. For this purpose, an antibody 
anti-membrane immunoglobulins was bound 
to the functionalized biochip as previously 
described. The biochip was then incubated in the 
presence of A20 cells at a concentration of 
5Exp6 cells/ml in 1 x PBS at RT for 2 hours. 
After several washes in 1 x PBS, the wafers 
were analyzed under a light microscope (Leika 
DM6000M). As experimental control it was used 
a biochip that was incubated with a cell line that 
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      Table 2. Thickness of biochips during fabrication steps. 
Chip SIO (nm) 
APTES+GA 
(nm) 
PA+Ab+M13 
phage (nm) χ2 
A 72.06±0.09 1.33±0.07 5.35±0.06 0.5 
B 72.56±0.09 2.10±0.09 2.35±0.05 0.4 
C 75.11±0.06 No treatment 0.47±0.03 0.4 
      χ2 is a measure of the deviation of sample from expectation. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
does not express membrane IgG (CB1) and a 
biochip lacking the antibody anti-IgG. As reported 
in Figure 5, the IgG-functionalized biochip was 
able to bind specifically the A20 cells (Panels A 
and B, Figure 5) whereas it did not recognize 
different cells (Panel C, Figure 5). In addition, 
A20 cells did not show non-specific binding to the 
biochip lacking antibody anti-IgG (Panel D, 
Figure 5) thus suggesting the versatility of the 
engineered biochip. 
 
CONCLUDING REMARKS                                      
In this work, we describe the use of the 
silicon technology in order to construct a 
biochip that allows the identification of specific 
ligand-receptor interactions. The micro-fabricated 
biochips we tested appear to be suitable to reveal 
several specific bindings such as that between 
a) an antibody and its ligand peptide, b) an 
antibody and a recombinat phage expressing an 
antibody ligand epitope and c) cell surface 
proteins and corresponding specific antibody. On 
the bases of the results obtained, we further plan 
to use this specific technology for anchoring 
phage virions to silicon surface and to select for 
the recognition of the phage virions by specific 
 
 
 
 
 
 
 
 
Figure 5. Binding of murine lymphoma cells (A20) 
to the silicon biochip. Optical images of the 
functionalized biochips treated with antibody anti-IgG 
(6,8 µM) and then incubated with A20 cells. (A) Before 
washes and (B) after washes (20 x enlargement). 
(C) Optical image after washes of the biochip 
functionalized with anti-IgG and incubated with CB1 
cells. (D) Optical image after washes of the biochip 
lacking anti-IgG and incubated with A20 cells.  
 
 
 
 
 
 
Figure 3. Fluorescence images of biochips after 
binding of labelled biomolecules. A) biochip 
after treatment with rhodamine-labelled protein A. 
B) biochip after incubation ON at 4 °C with rhodamine-
labelled UN1 mAb (1mg/ml in 1 x PBS, pH 7.5). 
C) biochip after incubation for 2 hours at RT with 
rhodamine-labelled peptide G23 (200 µM in 1 x PBS, 
pH 7.5). 
Molecular interactions on silicon biochips 
A
B
C
Figure 4. Fluorescence images of biochips after  
the interaction with labelled M13 phage. FITC 
labelled M13 phage was incubated with differently 
functionalized biochips according to the following 
schemes: A) SIO + APTES + GA + PA + AbAnti-P8; 
B) SIO + APTES + GA + PA + UN1 mAb; C) SIO + 
PA + AbAnti-P8. Left panels, biochips after washes 
with 1 x PBS; right panels, biochip after extensive 
dialysis against 1 x PBS. 
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T hybridoma cells. Once the system has been 
validated, the application of this technology will 
be expanded studying crude T cell populations 
obtained from different sources (i.e. tumor 
infiltrating lymphocytes and tissue target of 
autoimmune diseases). 
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